Argos Therapeutics (ARGS) Misses Q2 EPS by 15c

Argos Therapeutics (NASDAQ: ARGS) reported Q2 EPS of ($0.95), $0.15 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $107 thousand versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
• Hub Group faces credibility test as Q2 report looms Sept. 1